Cervical Pessary for Prevention of Spontaneous Preterm Birth in Singleton Pregnancies With Arrested Preterm Labor

December 17, 2019 updated by: Gabriele Saccone, Federico II University

Cervical Pessary for Prevention of Spontaneous Preterm Birth in Singleton Pregnancies With Arrested Preterm Labor: a Randomized Controlled Trial

Preterm birth (PTB) is a major cause of perinatal morbidity and mortality. Worldwide, about 15 million babies are born too soon every year, causing 1.1 million deaths, as well as short- and long-term disability in countless survivors.

Different strategies have been studied for prevention of spontaneous PTB (SPTB) in randomized controlled trials (RCTs), including progesterone, cerclage, cervical pessary, as well as lifestyle modification, such as smoking cessation, diet, aerobic exercise, and nutritional supplements. Most successful effort to reduce the incidence of SPTB have focused on asympatomatic women with risk factors, such as prior SPTB or short cervix. However, most SPTB occur in symptomatic women, i.e. women with preterm labor (PTL). Women with arrested PTL are at increased risk of SPTB.

The cervical pessary is a silicone device that has been used to prevent SPTB. The leading hypotheses for its mechanisms are two: that the pessary helps to keep the cervix closed, and that the pessary changes the inclination of the cervical canal so that the pregnancy weight is not directly above the internal os.

The aim of the study is to assess the efficacy of pessary in reducing preterm birth in women with arrested preterm labor

Study Overview

Status

Terminated

Conditions

Study Type

Interventional

Enrollment (Actual)

61

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Naples, Italy, 80100
        • University of Naples Federico II

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 50 years (ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Singleton gestations
  • Diagnosis of arrested PTL
  • 18-50 years of age
  • TVU CL ≤25mm at the time of randomization

Exclusion Criteria:

  • Multiple gestations
  • Rupture of membranes at the time of randomization
  • Known major fetal structural (i.e. defined as those that are lethal or require prenatal or postnatal surgery) or chromosomal abnormality
  • Fetal death at the time of randomization
  • Cerclage in situ at the time of randomization
  • Pessary in situ at the time of randomization
  • Vaginal bleeding at the time of randomization
  • Women who are unconscious, severly ill, mentally handicapped, or under the age of 18 years
  • Placenta previa and/or accreta
  • Ballooning of membranes outside the cervix into the vaginal or TVU CL = 0mm at the time of randomization
  • Painful and regular uterine contractions at the time of randomization

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: PREVENTION
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: SINGLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Pessary
Silicon device applied on the cervix
arabin pessary: silicon device
ACTIVE_COMPARATOR: No Pessary
standard care, no pessary
control group

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pre-term Birth
Time Frame: at the time of delivery
delivery before 37 weeks of gestations
at the time of delivery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pre-term Birth <34, <32, and <28 weeks
Time Frame: at the time of delivery
delivery before 34, 32, and 28 weeks
at the time of delivery
Mean gestational age at delivery in weeks
Time Frame: at the time of delivery
Mean gestational age at delivery in weeks
at the time of delivery
Mean latency in days
Time Frame: at the time of delivery
Time from randomization to delivery
at the time of delivery
Maternal side effects related to the intervention
Time Frame: at the time of delivery
any maternal adverse events
at the time of delivery
Chorioamnionitis
Time Frame: at the time of delivery
inflammation of the chorion and amnion by histopathological assessment after delivery
at the time of delivery
Composite adverse perinatal outcome
Time Frame: Between birth and 28 days of ag
Includes Nectrotizing Enterocolitis, Intraventricular Hemorrhage, Respiratory Distress syndrome, Bronchopolmunary dysplasia,Retinopathy of Prematurity, Blood-culture proven sepsis, Neonatal death.
Between birth and 28 days of ag

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

June 1, 2018

Primary Completion (ACTUAL)

September 4, 2019

Study Completion (ACTUAL)

November 1, 2019

Study Registration Dates

First Submitted

April 30, 2018

First Submitted That Met QC Criteria

May 18, 2018

First Posted (ACTUAL)

June 1, 2018

Study Record Updates

Last Update Posted (ACTUAL)

December 19, 2019

Last Update Submitted That Met QC Criteria

December 17, 2019

Last Verified

December 1, 2019

More Information

Terms related to this study

Other Study ID Numbers

  • 103/18

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

not decided yet

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Preterm Birth

Clinical Trials on arabin pessary

3
Subscribe